Page 61 - Revista Argentina de Transfusión 2-2019

13. Escolar, G., Fernandez-Gallego, V., Arellano-Rodrigo, E. et al. 28. Agnelli G, Buller HR, Cohen A, et al; AMPLIFY Investigators.
Reversal of apixaban induced alterations in hemostasis by dif- Oral apixaban for the treatment of acute venous thromboem-
ferent coagulation factor concentrates: significance of stud- bolism. N Engl J Med 2013;369(9):799–808
ies in vitro with circulating human blood. PLoS One 2013, 8(11): 29. Agnelli G, Buller HR, Cohen A, et al; PLIFY-EXT Investigators.
e78696. Apixaban for extended treatment of venous thromboembolism.
14. Arellano-Rodrigo, E., Lopez-Vilchez, I., Galan, A.M. el al. Coagu- N Engl J Med 2013;368(8):699–708
lation factor concentrates fail to restore alterations in fibrin 30. Granger CB, Alexander JH, McMurray JJ, et al; ARISTOTLE Com-
formation caused by rivaroxaban or dabigatran in studies with mittees and Investigators. Apixaban versus warfarin in patients
flowing blood from treated healthy volunteers. Transfus Med with atrial fibrillation. N Engl J Med 2011;365(11):981–992
Rev 2015, 29(4): 242-9. 31. Connolly SJ, Eikelboom J, Joyner C, et al; AVERROES Steering
15. Escolar,G., Arellano-Rodrigo, E., Lopez-Vilchez, I. et al. Rever- Committee and Investigators. Apixaban in patients with atrial
sal of Rivaroxabaninduced alterations on hemostasis by differ- fibrillation. N Engl J Med 2011;364(9):806–817
ent coagulation factor concentrates-in vitro studies with steady 32. Ogata K, Mendell-Harary J, Tachibana M, et al. Clinical safety,
and circulating human blood. Circ J 2015, 79 (2): 331-8. tolerability, pharmacokinetics, and pharmacodynamics of the
16. Sarode R, Milling Jr TJ, Refaai MA, et al. Efficacy and safety of novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin
a 4-factor prothrombin complex concentrate in patients on vi- Pharmacol 2010;50(7):743–753
tamin K antagonists presenting with major bleeding: a ran- 33. Bounameaux H, Camm AJ. Edoxaban: an update on the new
domized, plasma-controlled, phase IIIb study. Circulation oral direct factor Xa inhibitor. Drugs 2014;74(11):1209–1231
2013;128:1234–43. 34. Bauersachs R. Edoxaban: a new oral direct factor Xa inhibitor
17. Sarode R, Milling Jr TJ, Refaai MA, et al. Efficacy and safety of for the prevention and treatment of thromboembolic disorders.
a 4-factor prothrombin complex concentrate in patients on vi- Clin Investig 2014;4(7):619–639
tamin K antagonists presenting with major bleeding: a ran- 35. Fuji T,Wang CJ, Fujita S, et al. Safety and efficacy of edoxaban,
domized, plasma-controlled, phase IIIb study. Circulation an oral factor Xa inhibitor, versus enoxaparin for thrombopro-
2013;128:1234–43. phylaxis after total knee arthroplasty: the STARS E-3 trial.
18. Goldstein JN, Refaai MA, Milling Jr TJ, et al. Four-factor pro- Thromb Res 2014;134(6):1198–1204
thrombin complex concentrate versus plasma for rapid vita- 36. Fuji T, Wang CJ, Fujita S, Kawai Y, Kimura T, Tachibana S. Safe-
min K antagonist reversal in patients needing urgent surgical ty and efficacy of edoxaban, an oral factor xa inhibitor, for throm-
or invasive interventions: a phase 3b, open-label, non-inferiori- boprophylaxis after total hip arthroplasty in Japan and Taiwan.
ty, randomised trial. Lancet 2015;385:2077–87. J Arthroplasty 2014;29(12):2439–2446
19. Janssen Pharmaceuticals, Inc.. Xarelto (rivaroxaban) prescrib- 37. Fuji T, Fujita S, Kawai Y, et al. Safety and efficacy of edoxaban
ing information. Available at: https://www.xarelto-us.com/ in patients undergoing hip fracture surgery. Thromb Res 2014;
shared/product/xarelto/prescribinginformation.pdf; 2015. [Ac- 133(6):1016–1022
cessed February 23, 2016]. 38. Büller HR, Décousus H, Grosso MA, et al; Hokusai-VTE Investiga-
20. Bristol-Myers Squibb Company. Eliquis (apixaban) prescribing tors. Edoxaban versus warfarin for the treatment of symptomatic
information. Available at: http://packageinserts.bms.com/pi/ venous thromboembolism. N Engl J Med 2013;369(15): 1406–1415
pi_eliquis.pdf; 2015. [Accessed February 23, 2016]. 39. Giugliano RP, Ruff CT, Braunwald E, et al; ENGAGE AF-TIMI 48
21. Daiichi Sankyo, Inc.. Savaysa (edoxaban) prescribing informa- Investigators. Edoxaban versus warfarin in patients with atrial
tion. Available at:http://dsi.com/prescribing-information-port- fibrillation. N Engl J Med 2013;369(22):2093–2104
let/getPIContent?productName=Savaysa&inline=true; 2015. 40. Perzborn E, Strassburger J, Wilmen A, et al. In vitro and in vivo
[Accessed February 23, 2016]. studies of the novel antithrombotic agent BAY 59-7939—an oral,
22. Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and direct Factor Xa inhibitor. J Thromb Haemost 2005;3(3):514–521
pharmacokinetics after oral administration to humans. Drug 41. Eriksson BI, Borris LC, Friedman RJ, et al; RECORD1 Study
Metab Dispos 2009;37(1):74–81 Group. Rivaroxaban versus enoxaparin for thromboprophylaxis
23. Deeks ED. Apixaban: a review of its use in the prevention of after hip arthroplasty. N Engl J Med 2008;358(26):2765–2775
venous thromboembolismafter knee or hip replacement 42. Kakkar AK, Brenner B, Dahl OE, et al; RECORD2 Investigators.
surgery.Drugs 2012;72(9):1271–1291. Extended duration rivaroxaban versus short-termenoxaparin for
24. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. the prevention of venous thromboembolism after total hip ar-
Apixaban or enoxaparin for thromboprophylaxis after knee re- throplasty: a double-blind, randomised controlled trial. Lancet
placement. N Engl J Med 2009;361(6):594–604 2008;372(9632):31–39
25. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P; 43. Lassen MR, Ageno W, Borris LC, et al; RECORD3 Investigators.
ADVANCE-2 investigators. Apixaban versus enoxaparin for throm- Rivaroxaban versus enoxaparin for thromboprophylaxis after
boprophylaxis after knee replacement (ADVANCE-2): a randomised total knee arthroplasty. N Engl J Med 2008;358(26):2776–2786
double-blind trial. Lancet 2010;375(9717):807–815 44. Turpie AG, Lassen MR, Davidson BL, et al; RECORD4 Investiga-
26. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez tors Rivaroxaban versus enoxaparin for thromboprophylaxis after
LM; ADVANCE-3 Investigators. Apixaban versus enoxaparin for total knee arthroplasty (RECORD4): a randomised trial. Lancet
thromboprophylaxis after hip replacement. N Engl J Med 2010; 2009;373(9676):1673–1680
363(26):2487–2498. 45. Turpie AG, Lassen MR, Eriksson BI, et al. Rivaroxaban for the
27. Eriksson BI, Quinlan DJ, Eikelboom JW. Novel oral factor Xa prevention of venous thromboembolism after hip or knee ar-
and thrombin inhibitors in the management of thromboembo- throplasty. Pooled analysis of four studies. Thromb Haemost
lism. Annu Rev Med 2011;62:41–57 2011;105(3):444–453

Curso AAHITC de Médico Especialista en Hemoterapia Vol. XLV / N° 2 / 2019 Asociación Argentina Pág. 145
e Inmunohematología. Formación en Medicina Págs. 139 / 147 de Hemoterapia,
Transfusional y Terapia Celular. Inmunohematología
Manejo del sangrado en pacientes con drogas anti y Terapia Celular
Factor X